Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q2 2025 (June 30)2holders
0new positions
0sold out
$0.10avg. 13F price*
At the end of Q2 2025, 2 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Heights Capital Management, Inc. ($4K) and UBS Group AG ($420).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 2 holders
| Heights Capital Management, Inc. | — | No change | 41,251 | $4K |
| UBS Group AG | — | No change | 4,195 | $420 |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.